IGC Pharma, Inc. (IGC)
IGC moved a median of +0.55% 30 minutes after news, and -0.30% by the close. How IGC actually reacts to news — the realized, point-in-time move the market made, measured across 209 labeled events over the last three years with zero look-ahead.
IGC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 207 |
| 30-min | +0.55% | 57% | 209 |
| 60-min | +0.06% | 53% | 209 |
| to close | -0.30% | 45% | 204 |
| Middle 50% of IGC reactions | -1.61% to +2.05% |
|---|---|
| Median reaction (30-min) | +0.55% |
| Measured reactions | 209 |
Half of all IGC Pharma, Inc. news events land between -1.61% and +2.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IGC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IGC's baseline. Nothing else.
Recent IGC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment | Press release | ACCESS Newswire | -1.19% | -1.71% | |
| IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 | Press release | ACCESS Newswire | +1.00% | -5.19% | |
| IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure | Press release | ACCESS Newswire | -1.82% | -1.82% | |
| Form 10-Q IGC Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.82% | -1.82% | |
| IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout | Press release | ACCESS Newswire | +3.33% | +4.07% | |
| IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign | Press release | ACCESS Newswire | -1.01% | -8.40% | |
| Form 8-K IGC Pharma, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | +1.91% | |
| IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow | Press release | ACCESS Newswire | +4.33% | +1.46% | |
| IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company | Press release | ACCESS Newswire | +0.00% | -0.21% | |
| Form 8-K IGC Pharma, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.21% | |
| IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow | Press release | ACCESS Newswire | +0.48% | -1.85% | |
| IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis | Press release | ACCESS Newswire | +3.89% | +0.43% | |
| Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts | Press release | ACCESS Newswire | -0.17% | -2.56% | |
| Form 8-K IGC Pharma, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -2.56% | |
| IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis | Press release | ACCESS Newswire | +2.19% | +0.69% | |
| IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment | Press release | ACCESS Newswire | +1.70% | -0.32% | |
| Form 10-Q IGC Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.69% | -0.69% | |
| IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference | Press release | ACCESS Newswire | +1.94% | -2.75% | |
| IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase | Press release | ACCESS Newswire | +0.65% | -0.02% | |
| IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion | Press release | ACCESS Newswire | -0.41% | +11.93% | |
| Form 8-K IGC Pharma, Inc. For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -0.44% | |
| IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia | Press release | ACCESS Newswire | -3.93% | -3.04% | |
| IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout | Press release | ACCESS Newswire | +5.41% | +4.76% | |
| Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts | Press release | ACCESS Newswire | +4.34% | -0.28% | |
| IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease | Press release | ACCESS Newswire | +0.04% | +0.00% | |
| Form 8-K IGC Pharma, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | +3.14% | |
| IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness | Press release | ACCESS Newswire | -0.45% | -4.66% | |
| New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning | Press release | ACCESS Newswire | +2.71% | +3.56% | |
| IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 | Press release | ACCESS Newswire | +0.00% | -1.09% | |
| Form 10-KT IGC Pharma, Inc. For: Dec 31 | SEC filing · Form 10-KT | SEC EDGAR | +0.00% | -1.09% | |
| IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 | Press release | ACCESS Newswire | -0.67% | -2.72% | |
| Form 8-K IGC Pharma, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | -2.04% | |
| IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research | Press release | ACCESS Newswire | -4.46% | -6.62% | |
| IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets | Press release | ACCESS Newswire | +1.03% | +2.80% | |
| IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial | Press release | ACCESS Newswire | -5.16% | -5.00% | |
| IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances | Press release | ACCESS Newswire | -9.48% | -8.57% | |
| IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets | Press release | ACCESS Newswire | -1.30% | +1.07% | |
| IGC Pharma Announces Equity Research Update by Alliance Global Partners | Press release | ACCESS Newswire | -0.08% | +3.67% | |
| IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center | Press release | ACCESS Newswire | +2.31% | +4.28% | |
| IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation | Press release | ACCESS Newswire | -0.47% | +0.18% | |
| IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York | Press release | ACCESS Newswire | -0.34% | +2.62% | |
| IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia | Press release | ACCESS Newswire | +0.65% | -2.63% | |
| Form 8-K IGC Pharma, Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | -2.79% | |
| IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability | Press release | ACCESS Newswire | -2.46% | -2.79% | |
| IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial | Press release | ACCESS Newswire | +0.51% | +0.10% | |
| Form 8-K IGC Pharma, Inc. For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +0.10% | |
| IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum | Press release | ACCESS Newswire | -3.52% | -11.22% | |
| Form 8-K IGC Pharma, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -0.72% | +0.60% | |
| IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines | Press release | ACCESS Newswire | -3.66% | -6.02% | |
| IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." | Press release | ACCESS Newswire | +2.38% | +14.77% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IGC section they belong to.
Where else IGC is measured.
IGC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is IGC Pharma, Inc.'s median reaction calculated?
Every labeled IGC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 209 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 57% of IGC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IGC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.